Ucb SA
XBRU:UCB

Watchlist Manager
Ucb SA Logo
Ucb SA
XBRU:UCB
Watchlist
Price: 247.5 EUR 3.17% Market Closed
Market Cap: 48.1B EUR

UCB's latest stock split occurred on Jan 4, 1999

The company executed a 100-for-1 stock split, meaning that for every share held, investors received 100 new shares.

The adjusted shares began trading on Jan 4, 1999. This was the only stock split in UCB's history.

Last Splits:
Jan 4, 1999
100-for-1
Pre-Split Price
N/A
Post-Split Price
37.1498
Before
After
Last Splits:
Jan 4, 1999
100-for-1

Ucb SA
Stock Splits History

UCB Stock Splits Timeline
Jan 4, 1999
Jan 4, 1999
Split 100-for-1
x100
Pre-Split Price
N/A
Post-Split Price
37.1498
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
47.5 47.5 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
60.6 60.6 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Ucb SA
Glance View

Market Cap
47B EUR
Industry
Pharmaceuticals

UCB SA, a Belgian multinational biopharmaceutical company, stands at the forefront of innovation in the medical field, committed to creating value by discovering new ways to treat severe diseases. Founded in 1928, UCB has transformed over the decades from its initial focus in chemicals to pioneering developments in advanced therapeutics targeting central nervous system disorders and immunology. Anchored by a robust research pipeline and a keen focus on rare diseases and specialty care, UCB has established a strong presence globally, reflecting its strategic pivot toward patient-centric approaches. With primary research facilities stationed in Braine-l'Alleud, Belgium, and Slough, UK, the company's scientific endeavors are bolstered by collaborations with research institutions worldwide, fostering an environment ripe for breakthrough discoveries. Financially, UCB's revenue streams are predominantly derived from its established portfolio of blockbuster drugs, such as Cimzia, Vimpat, and Keppra, which serve as critical lifelines for patients dealing with autoimmune diseases, epilepsy, and other chronic conditions. The company thrives on a dynamic business model that combines in-house scientific research with strategic partnerships and acquisitions to enhance its competitive edge. This synergy not only facilitates sustained growth in its core markets but also drives expansion into emerging ones, underscoring its global reach. By reinvesting substantial portions of its earnings into research and development, UCB ensures a steady pipeline of new products, thereby maintaining its stature in the highly competitive biopharmaceutical landscape. Through such strategic maneuvers, UCB aligns its operations with the overarching goal of delivering transformative therapies that improve the quality of life for patients around the world.

UCB Intrinsic Value
234.43 EUR
Overvaluation 5%
Intrinsic Value
Price
Back to Top